Anti-infectives to lead Indian domestic market
Cardiovascular, central nervous system, antidiabetic and gastrointestinal therapy areas likely to fuel future growth
Anti-infective medicines are set to lead growth in the Indian domestic pharma market in the coming days. Lifestyle segments like cardiovascular, central nervous system, antidiabetic, and gastrointestinal would be fuelling future growth.
Anticancer was the fastest growing segment and grew at 24.9%. Some other rapidly growing segments were respiratory at 9.3%, antidiabetic at 14.6% and dermatology at 10.6%. The top five therapeutic segments contributed 57% to total domestic revenues.
Moreover, 10 multinational (MNC) pharmaceutical companies had 42 brands in the list of top 100 brands. GlaxoSmithKline Pharma had nine brands, while Abbott India and Sanofi India followed with seven brands each, clearly showing that MNC pharma companies have been highly successful in brand building and nurturing their brands in the domestic pharma market in India.
Human Mixtard from Novo Nordisk is the largest selling product in the domestic market with revenues of Rs 3.49bn per annum.
